Purpose
Prostate cancer is considered the most common type of malignancy in men worldwide. At least 2 million men in the United States develop or have prostate cancer with 200,000 new cases diagnosed annually, leading to approximately 30,000 deaths per year. Imaging plays an important role in many aspects of the management of this disease. Since prostate-specific membrane antigen is well known to be overexpressed in most prostate cancers, efforts have been made to develop ligands for this target, either for PET/CT imaging or radioligand Therapy.Whole-body...
Methods and materials
110 subjects with histopathology confirmed prostatic adenocarcinoma were enrolled in this prospective study. Gleason score ranged from 6(3+3) to 10(5+5). 8 subjects had a Gleason score of 3+3(7.3%), 22 subjects had a Gleason score of 3+4(20%), 25 subjects had a Gleason score of 4+3(22.7%), 26 subjects had a Gleason score of 4+4(23.6%), 18 subjects had a Gleason score of 4+5(16.4%), 8 subjects had a Gleason score of 5+4(7.2), 2 subjects had a Gleason score of 5+5(1.8%) and 1 subject with undefined Gleason score (0.9%). The...
Results
All the images were of high quality. For subjects with a PSA less than 0.2 ng/ml the detection rate was 43%(3/7), with a PSA between 0.2 ng/ml to 0.5 ng/ml was 50%(9/18), with a PSA between 0.5 ng/ml to 1.0 ng/ml was 68.8%(11/16), with a PSA between 1.0 ng/ml to 2.0 ng/ml was 61.5%(8/13), with a PSA between 2.0 ng/ml to 5.0 ng/ml was 93.8%(15/16) and with a PSA of more than 5.0 ng/ml the detection rate was 100%(40/40). The average detection rate of 68Ga-PSMA-11...
Conclusion
68Ga-PSMA-11 PET/CT is a safe imaging technique with a considerably higher detection rate in comparison with different conventional imaging modalities in patients with prostate cancer. There is a direct correlation between PSA level and 68Ga-PSMA-11 positivity with about 94% detection rate for PSA levels above 2.0 ng/ml.
Personal information and conflict of interest
A. Gaber:
Nothing to disclose
R. Núñez:
Nothing to disclose
E. Delpassand:
Nothing to disclose
References
1. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J Clin 70(1) (2020) 7-30.